NAPSR news: J & J Announces Strong Second Quarter Results- Pharmaceutical Sales Soar

Johnson & Johnson a proven industry leader in the healthcare sector is the first big pharma corporation to unveil the second quarter results for 2014. The pharmaceuticals division made an impressive contribution to the strong sales growth.
By:
 
WASHINGTON - July 16, 2014 - PRLog -- Johnson & Johnson announced on July 15, 2014 second quarter results for 2014 with 19.5 billion in sales, a remarkable 9.1% increase compared to the second quarter of 2013.

“Our strong second-quarter results reflect the continued success of our new product launches and the progress we have made in achieving our near-term priorities,” said Alex Gorsky, Chairman and Chief Executive Officer.  “Significant advancements are being made in the treatment options and access to care for patients and customers around the world. Our diversified business model, focus on long-term growth drivers and talented colleagues position us well in this evolving and dynamic global health care market.”

The Pharmaceuticals division was a key player in the significant sales boost for J & J. Worldwide pharma sales generated $8.5 billion for the second quarter and sales increased 21.1% from last year’s quarter on a total and operational basis. According to the news released issued by J & J, “Domestic sales increased 36.6%.  International sales increased 6.8% which reflected an operational increase of 6.9% and a negative currency impact of 0.1%.”

Strong pharmaceutical sales were fueled by new product launches which include:
·   OLYSIO®/SOVRIAD® (simeprevir )-  treatment of chronic hepatitis C in adult patients
·   XARELTO® (rivaroxaban), - an oral anticoagulant
·   ZYTIGA® (abiraterone acetate), oral, once daily medication combined with prednisone to treat metastatic, castration-resistant prostate cancer
·   INVOKANA®(canagliflozin), - treatment of adults with type 2 diabetes
·   IMBRUVICA® (ibrutinib), - kinase inhibitor to treat mantle cell lymphoma and chronic lymphocytic leukemia in patients who have had at least one prior therapy

Among  J & J’s established prescription portfolio, other products that contributed to the sales growth include:
·   STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis
·   REMICADE® (infliximab) and SIMPONI®/SIMPONI® ARIA™ (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases
·   INVEGA®  SUSTENNA®/XEPLION® (paliperidone palmitate, injectable atypical antipsychotic for the treatment of schizophrenia in adults
·   PREZISTA® (darunavir), a treatment for HIV

J & J also received approval during the quarter from the  U.S. Food and Drug Administration (FDA) and the European Commission (EC) for SYLVANT® (siltuximab) created for the treatment of patients with multicentric Castleman’s disease, which also gave rise to the revenue growth.

NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD!
With such industry leaders posting gains in profitability, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to market their product both proficiently and efficiently.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!
The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information.

Contact
NAPSRx
sneece@napsronline.org
1-800-284-1060
End
Source: » Follow
Email:***@napsronline.org Email Verified
Tags:Pharmaceutical Sales, Cnpr Certification, Napsrx, Sales Marketing, Sales Representatives
Industry:Biotech, Health
Location:Washington - District of Columbia - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Page Updated Last on: Jul 16, 2014
NAPSRx PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share